Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 15.77
(0.9%)
CNY 15.77
(0.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.4 Million CNY | -95.08% |
| 2022 | 69.14 Million CNY | -31.94% |
| 2021 | 101.58 Million CNY | 108.67% |
| 2020 | 48.68 Million CNY | 304.94% |
| 2019 | -23.75 Million CNY | -11.9% |
| 2018 | -21.22 Million CNY | 25.58% |
| 2017 | -28.52 Million CNY | 48.95% |
| 2016 | -55.87 Million CNY | -5.06% |
| 2015 | -53.18 Million CNY | -110.99% |
| 2014 | -25.2 Million CNY | -6.37% |
| 2013 | -23.69 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.93 Million CNY | 93.18% |
| 2024 Q1 | -28.31 Million CNY | -69.6% |
| 2024 Q3 | 34.9 Million CNY | 1908.24% |
| 2023 Q4 | -16.69 Million CNY | -668.38% |
| 2023 Q3 | -2.17 Million CNY | -111.76% |
| 2023 FY | 3.4 Million CNY | -95.08% |
| 2023 Q1 | 3.79 Million CNY | 162.6% |
| 2023 Q2 | 18.46 Million CNY | 386.26% |
| 2022 Q2 | 65.69 Million CNY | 974.44% |
| 2022 Q1 | -7.51 Million CNY | -125.61% |
| 2022 FY | 69.14 Million CNY | -31.94% |
| 2022 Q4 | -6.06 Million CNY | -156.43% |
| 2022 Q3 | 10.75 Million CNY | -83.63% |
| 2021 Q2 | 19.68 Million CNY | -3.7% |
| 2021 Q4 | 29.33 Million CNY | -8.69% |
| 2021 Q1 | 20.43 Million CNY | 1349.9% |
| 2021 FY | 101.58 Million CNY | 108.67% |
| 2021 Q3 | 32.12 Million CNY | 63.24% |
| 2020 Q2 | 10.63 Million CNY | 626.64% |
| 2020 FY | 48.68 Million CNY | 304.94% |
| 2020 Q3 | 22.66 Million CNY | 113.0% |
| 2020 Q4 | -1.63 Million CNY | -107.22% |
| 2020 Q1 | 1.46 Million CNY | 115.0% |
| 2019 Q1 | -15.9 Million CNY | 0.0% |
| 2019 FY | -23.75 Million CNY | -11.9% |
| 2019 Q4 | -9.76 Million CNY | 0.0% |
| 2018 Q1 | 330.05 Thousand CNY | -91.53% |
| 2018 Q2 | 330.05 Thousand CNY | 0.0% |
| 2018 FY | -21.22 Million CNY | 25.58% |
| 2017 Q4 | 3.89 Million CNY | 0.0% |
| 2017 FY | -28.52 Million CNY | 48.95% |
| 2017 Q1 | -6.75 Million CNY | 62.91% |
| 2017 Q3 | 3.89 Million CNY | 157.67% |
| 2017 Q2 | -6.75 Million CNY | 0.0% |
| 2016 Q1 | -9.71 Million CNY | 34.71% |
| 2016 Q4 | -18.22 Million CNY | 0.0% |
| 2016 FY | -55.87 Million CNY | -5.06% |
| 2016 Q3 | -18.22 Million CNY | -87.62% |
| 2016 Q2 | -9.71 Million CNY | 0.0% |
| 2015 Q3 | -14.87 Million CNY | -27.02% |
| 2015 Q2 | -11.71 Million CNY | 0.0% |
| 2015 Q1 | -11.71 Million CNY | 0.0% |
| 2015 FY | -53.18 Million CNY | -110.99% |
| 2015 Q4 | -14.87 Million CNY | 0.0% |
| 2014 FY | -25.2 Million CNY | -6.37% |
| 2013 FY | -23.69 Million CNY | 0.0% |